Statement Of Cash Flows [Abstract]

ERYTECH Pharma S.A. - Filing #2810992

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Income taxes paid (refund), classified as operating activities
294,000 EUR
3,000 EUR
2,000 EUR
Cash flows from (used in) operating activities
24 428 EUR
31 763 EUR
56 770 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
10,000 EUR
EUR
EUR
Proceeds from sales of property, plant and equipment, classified as investing activities
23,000 EUR
37 630 EUR
EUR
Purchase of property, plant and equipment, classified as investing activities
217,000 EUR
85,000 EUR
298,000 EUR
Purchase of intangible assets, classified as investing activities
EUR
EUR
EUR
Cash flows from (used in) investing activities
171,000 EUR
38 126 EUR
345,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
EUR
EUR
34 631 EUR
Proceeds from issuing other equity instruments
EUR
EUR
EUR
Proceeds from borrowings, classified as financing activities
EUR
3 081 EUR
12 157 EUR
Repayments of borrowings, classified as financing activities
2 725 EUR
3 081 EUR
EUR
Payments of lease liabilities, classified as financing activities
1 052 EUR
1 545 EUR
1 702 EUR
Cash flows from (used in) financing activities
3 716 EUR
1 768 EUR
44 712 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
342,000 EUR
495,000 EUR
1 656 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
28 315 EUR
5 090 EUR
10 747 EUR
Cash and cash equivalents
10 474 EUR
38 789 EUR
33 699 EUR
44 446 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.